Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Neoadjuvant Radiation for Soft Tissue Sarcoma
NCT03338959Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2018
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in soft tissue sarcoma (STS), sponsored by Fred Hutchinson Cancer Center. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03338959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338959.